Literature DB >> 20224949

[Patent blue V : inert dye or potent allergen].

V Rogler1, C Röhm, J Reutershan.   

Abstract

Patent blue V is widely used as a food dye. Clinically, patent blue V dye has been increasingly used in oncological surgery to identify the sentinel lymph nodes in breast cancer and other malignancies. The case of a patient who developed severe anaphylactic shock to subcutaneous injection of patent blue V during breast surgery is presented. The clinical course and the anesthesiological management are presented, and the pitfalls that may delay the correct diagnosis are highlighted.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20224949     DOI: 10.1007/s00101-010-1700-3

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  13 in total

1.  Anaphylactic reaction to patent blue V after sentinel lymph node biopsy.

Authors:  P Dewachter; C Mouton-Faivre; A Benhaijoub; F Abel-Decollogne; P M Mertes
Journal:  Acta Anaesthesiol Scand       Date:  2006-02       Impact factor: 2.105

2.  Severe anaphylactic shock to Patent Blue V with cardiac arrest during breast carcinoma surgery with lymphatic mapping.

Authors:  Laurent Thierrin; Daniel Steiger; Jean-Philippe Zuber; François Spertini; Yves Brunisholz; Jean-François Delaloye
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2007-10-29       Impact factor: 2.435

Review 3.  A comparison of the adverse reactions associated with isosulfan blue versus methylene blue dye in sentinel lymph node biopsy for breast cancer.

Authors:  Sarmela Thevarajah; Tara L Huston; Rache M Simmons
Journal:  Am J Surg       Date:  2005-02       Impact factor: 2.565

Review 4.  Cardiovascular emergencies in the cancer patient.

Authors:  D L Keefe
Journal:  Semin Oncol       Date:  2000-06       Impact factor: 4.929

5.  Pulse oximetry declines due to intradermal isosulfan blue dye: a controlled prospective study.

Authors:  Reza Momeni; Stephan Ariyan
Journal:  Ann Surg Oncol       Date:  2004-04       Impact factor: 5.344

6.  Adverse reactions to patent blue V dye - The NEW START and ALMANAC experience.

Authors:  L Barthelmes; A Goyal; R G Newcombe; F McNeill; R E Mansel
Journal:  Eur J Surg Oncol       Date:  2009-11-24       Impact factor: 4.424

7.  Anaphylaxis to patent blue V: a case series and proposed diagnostic protocol.

Authors:  R A Haque; A Wagner; J A Whisken; S M Nasser; P W Ewan
Journal:  Allergy       Date:  2009-11-20       Impact factor: 13.146

8.  [Immediate patent blue-induced hypersensitivity during sentinel node detection: The value of cutaneous tests].

Authors:  G Jeudy; N Louvier; T Rapennes; E Goujon; J Fraisse; S Dalac-Rat; E Collet
Journal:  Ann Dermatol Venereol       Date:  2008-06-19       Impact factor: 0.777

Review 9.  Trastuzumab (Herceptin)-associated cardiomyopathy presented as new onset of complete left bundle-branch block mimicking acute coronary syndrome: a case report and literature review.

Authors:  Chung-Ming Tu; Kai-Ming Chu; Shin-Ping Yang; Shu-Mung Cheng; Wen-Been Wang
Journal:  Am J Emerg Med       Date:  2009-09       Impact factor: 2.469

10.  Anaphylaxis to dyes during the perioperative period: reports of 14 clinical cases.

Authors:  Paul Michel Mertes; Jean Marc Malinovsky; Claudie Mouton-Faivre; Marie Caroline Bonnet-Boyer; Abdelhaouad Benhaijoub; François Lavaud; Jocelyne Valfrey; James O'Brien; Philippe Pirat; Laurent Lalourcey; Pascal Demoly
Journal:  J Allergy Clin Immunol       Date:  2008-06-12       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.